This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Read on for our views on how standardized, adaptable infrastructure for medicalimaging AI will ultimately improve the efficiency and precision of radiological assessments. AI can be leveraged to make incremental improvements at every stage of the medicalimaging pipeline, beyond the tasks well-suited for a large language model.
Lantheus MedicalImaging has appointed a new chief medical officer (CMO) and a new chief science officer (CSO). He will oversee Lantheus’ research and development organization, including research and pharmaceutical development, regulatory affairs, clinical development, medical affairs, and isotope strategy.
Administration of the therapeutic dose took place as part of an ongoing Phase I/IIa theranostic clinical trial conducted by Clarity Pharmaceuticals to investigate the safety and efficacy of Cu-67 SARTATE in pediatric patients with high-risk neuroblastoma.
and Project Data Sphere, a nonprofit initiative of the CEO Roundtable on Cancer, are partnering to improve tumor assessments using AI-enabled tools for clinical trials and cancer care. Food and Drug Administration (FDA), includes stakeholders and experts from across the pharmaceutical industry and academia.
"By not separating radiologist assistant reimbursement policies into different payment categories by service location, the adoption of MARCA would enable radiologists to devote more focused time to reviewing and interpreting complex medicalimages or urgent cases," the ASRT has said.
milla1cf Fri, 06/21/2024 - 20:24 June 21, 2024 — GE HealthCare , a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MediView XR Inc., Disclaimer: OmnifyXR is intended to be used adjunctively to standard of care imaging.
Radiologists in Ukraine have shared stories on their experiences, from living in the basement of their respective clinics to treat patients while evading bombings, to adjusting their workflows to continue delivering care. One radiologist based in Ukraine shared her perspective on the current state of medicalimaging in Ukraine.
BWXT Medical will collaborate closely with NorthStar, a global innovator in the development, production and commercialization of radiopharmaceuticals used for therapeutic applications and medicalimaging, to streamline production processes, enhance safety protocols and innovate new methods of isotope generation.
Different types of medicalimaging response criteria: morphological measures In oncology clinical trials, therapy is generally assessed using imaging response criteria involving imaging biomarkers. criteria, and therefore is the most used metric to assess efficacy in oncology clinical trials for solid tumors.
The project is the second funded and supported by NEURii, a global collaboration between the pharmaceutical company Eisai, Gates Ventures, the University of Edinburgh, the medical research charity LifeArc and the national health data science institute Health Data Research UK.
The agents affected include some of the most widely used contrast products in medicalimaging. The recommendation was issued by the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA), the primary body in the European Union responsible for regulating pharmaceuticals.
This unit will enable us to develop and manufacture patient doses for pharmaceutical or biotechnology companies as well as share our radiopharmaceutical development and commercialization expertise with them where they may require additional infrastructure, resources or the specialized knowledge required for complex radiopharmaceutical development.
GE HealthCare expects to leverage MIM Software’s imaging analytics and digital workflow capabilities across various care areas to accelerate innovation and differentiate its solutions for the benefit of patients and healthcare systems around the world.
Clinical trials for MASH drugs rely on various imaging modalities to provide quantitative and qualitative data regarding liver health, fat content, fibrosis, and inflammation.
Nucleus will use NorthStar’s Ac-225 for their customers’ radioligand pharmaceutical programs. Clinical research and commercial use of Ac-225 have been constrained by chronic short supply due to limitations of current production technology. President and Chief Executive Officer of NorthStar Medical Radioisotopes.
We organize all of the trending information in your field so you don't have to. Join 5,000 users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content